Resources
35 Results (showing 11 - 20)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 9/29/2021 (updated 4/3/2024)
In this re-welcome session, HRSA Project Officers shared reminders and updates about grant deliverables, the Evaluation Team will gave updates, and Technical Expert Leads discussed new and ongoing technical assistance available to Implementation I, Implementation II and MAT-Expansion grantees.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Representatives from the JBS/HRSA evaluation team presented information on Performance Improvement Measurement System deliverables and answer grantee questions.
Rebecca Schachtner, PhD, JBS International
Posted 10/27/2021 (updated 4/3/2024)
Posted 11/11/2021 (updated 4/3/2024)
Performance Improvement Measurement System
Posted 2/9/2022 (updated 3/26/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. These measures are pending OMB clearance and are subject to revision. This page contains the RCORP data collection resources for the Psychostimulant Support grantees only.
These documents will be updated as new guidance or data sources are identified. We encourage you to bookmark this page so you have the latest version available. Please send any measure-related questions to your HRSA Project Officer or email: rcorp-eval@jbsinternational.com.
Posted 3/23/2022 (updated 3/27/2024)
The JBS evaluation team will review and provide guidance on the PIMS measures that are most problematic for grantees and the new PIMS measures that are pending OMB approval. They will also highlight ways that consortiums can use their data dashboards to highlight successes and areas for improvement as they work to obtain funding and motivate and engage stakeholders.
Posted 4/20/2022 (updated 3/27/2024)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Posted 5/24/2022 (updated 3/27/2024)
These contingency management resources include a statement and advisory opinions from the United States Department of Health and Human Services Office of Inspector General. Additionally, the Contingency Management factsheet provides an overview of the approach.
Posted 6/7/2022 (updated 3/27/2024)
This session had three presenters who covered contingency management, prevention of stimulant use for children, and peer support.